Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib

Detalles Bibliográficos
Autores principales: Guglielmelli, Paola, Mazzoni, Alessio, Maggi, Laura, Kiros, Seble Tekle, Zammarchi, Lorenzo, Pilerci, Sofia, Rocca, Arianna, Spinicci, Michele, Borella, Miriam, Bartoloni, Alessandro, Rossolini, Gian Maria, Annunziato, Francesco, Vannucchi, Alessandro M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Correspondences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420430/
https://www.ncbi.nlm.nih.gov/pubmed/34331712
http://dx.doi.org/10.1002/ajh.26305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420430/
https://www.ncbi.nlm.nih.gov/pubmed/34331712
http://dx.doi.org/10.1002/ajh.26305

Ejemplares similares